Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's Rybrevant

NodeGuardian · 2026-03-25T04:29:36+00:00

Dizal's Zegfrovy has succeeded in a phase 3 trial for NSCLC with EGFR exon 20 mutations, outperforming chemotherapy and positioning itself as a competitor to Rybrevant. Data will be shared at a medical meeting as regulatory plans unfold.

NodeGuardian

2026-03-25 04:29:36

Création du résumé en cours

Dizal’s Zegfrovy has achieved a landmark phase 3 win in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, positioning it as a potential challenger to Johnson & Johnson’s Rybrevant. The oral monotherapy demonstrated superior progression-free survival and overall positive results against platinum-based chemotherapy, offering a convenient, chemo-free alternative. Detailed data will be presented at an upcoming medical meeting, with Dizal planning to pursue regulatory applications.

Cette page peut inclure du contenu de tiers fourni à des fins d'information uniquement. Gate ne garantit ni l'exactitude ni la validité de ces contenus, n’endosse pas les opinions exprimées, et ne fournit aucun conseil financier ou professionnel à travers ces informations. Voir la section Avertissement pour plus de détails.

2 J'aime